Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9
Authors
Keywords
-
Journal
PHARMACOLOGICAL RESEARCH
Volume 184, Issue -, Pages 106439
Publisher
Elsevier BV
Online
2022-09-12
DOI
10.1016/j.phrs.2022.106439
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
- (2022) Yahao Zhang et al. CLINICAL THERAPEUTICS
- Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction
- (2022) Gregory G. Schwartz et al. CURRENT OPINION IN LIPIDOLOGY
- Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients
- (2022) Ziwei Ou et al. Frontiers in Cardiovascular Medicine
- PCSK9: a view beyond the canonical cholesterol lowering impact
- (2021) Chiara Macchi et al. AMERICAN JOURNAL OF PATHOLOGY
- Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)
- (2021) Maciej Banach et al. PHARMACOLOGICAL RESEARCH
- Turnover Rates of the Low-Density Lipoprotein Receptor and PCSK9: Added Dimension to the Cholesterol Homeostasis Model
- (2021) Mohamad Dandan et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Combination lipid-lowering therapy as first-line strategy in very high-risk patients
- (2021) Kausik K Ray et al. EUROPEAN HEART JOURNAL
- PCSK9 Induces Tissue Factor Expression by Activation of TLR4/NFkB Signaling
- (2021) Valentina Scalise et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease
- (2021) Álvaro Petersen-Uribe et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies
- (2021) Carlota Oleaga et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol
- (2021) Jing Gao et al. Frontiers in Physiology
- Clinical approach to the inflammatory etiology of cardiovascular diseases
- (2020) Massimiliano Ruscica et al. PHARMACOLOGICAL RESEARCH
- Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE Study
- (2020) Nicola Ferri et al. ATHEROSCLEROSIS
- Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period
- (2020) Thorsten M. Leucker et al. CIRCULATION
- Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial
- (2020) Rafael Diaz et al. European Journal of Preventive Cardiology
- PCSK9 Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36
- (2020) Zhiyong Qi et al. CIRCULATION
- Early Initiation of Evolocumab Markedly Reduces Low-Density Lipoprotein Cholesterol Levels After Myocardial Infarction
- (2020) Tomoaki Okada et al. JACC-Cardiovascular Interventions
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary
- (2019) Scott M. Grundy et al. CIRCULATION
- ‘Ten Commandments’ for the Fourth Universal Definition of Myocardial Infarction 2018
- (2019) Kristian Thygesen EUROPEAN HEART JOURNAL
- PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention
- (2019) Francesco Paciullo et al. THROMBOSIS AND HAEMOSTASIS
- Recombinant LCAT (Lecithin:Cholesterol Acyltransferase) Rescues Defective HDL (High-Density Lipoprotein)-Mediated Endothelial Protection in Acute Coronary Syndrome
- (2019) Alice Ossoli et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PCSK9 inhibition and inflammation: A narrative review
- (2019) Massimiliano Ruscica et al. ATHEROSCLEROSIS
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Platelet function and activation markers in primary hypercholesterolemia treated with PCSK9 monoclonal antibody: a 12-month follow-up
- (2019) Cristina Barale et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis
- (2019) Peter R Sinnaeve et al. EUROPEAN HEART JOURNAL
- Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
- (2018) Michael D. Shapiro et al. ANNALS OF INTERNAL MEDICINE
- PCSK9 inhibitors in clinical practice: Delivering on the promise?
- (2018) Robert M. Stoekenbroek et al. ATHEROSCLEROSIS
- Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders
- (2018) Massimiliano Ruscica et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
- (2018) Sreeneeranj Kasichayanula et al. CLINICAL PHARMACOKINETICS
- PCSK9 as a Positive Modulator of Platelet Activation
- (2018) Marina Camera et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 induces a pro-inflammatory response in macrophages
- (2018) Chiara Ricci et al. Scientific Reports
- Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial
- (2018) Konstantinos C. Koskinas et al. CLINICAL CARDIOLOGY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study
- (2017) Eliano P. Navarese et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab
- (2017) Nihar R. Desai et al. JAMA Cardiology
- Evaluation of plasma PCSK9 concentrations, transcript of LDL receptor, as well as the total number of monocyte LDL receptors in acute coronary syndrome patients
- (2016) Paweł Burchardt et al. Cardiology Journal
- PCSK9 Association With Lipoprotein(a)Novelty and Significance
- (2016) Hagai Tavori et al. CIRCULATION RESEARCH
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
- (2016) Alberico L. Catapano et al. EUROPEAN HEART JOURNAL
- Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta
- (2015) Zufeng Ding et al. ANTIOXIDANTS & REDOX SIGNALING
- Cross-talk between LOX-1 and PCSK9 in vascular tissues
- (2015) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective
- (2015) Tomas Jernberg et al. EUROPEAN HEART JOURNAL
- Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line
- (2015) Massimiliano Ruscica et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Removal of Plasma Mature and Furin-Cleaved Proprotein Convertase Subtilisin/Kexin 9 by Low-Density Lipoprotein-Apheresis in Familial Hypercholesterolemia: Development and Application of a New Assay for PCSK9
- (2015) Mika Hori et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice
- (2015) Vikram Ravindra Shende et al. JOURNAL OF LIPID RESEARCH
- A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects
- (2014) Catherine Lunven et al. Cardiovascular Therapeutics
- 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: Executive Summary
- (2014) Ezra A. Amsterdam et al. CIRCULATION
- Isolation and characterization of the circulating truncated form of PCSK9
- (2014) Bomie Han et al. JOURNAL OF LIPID RESEARCH
- Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies
- (2014) Naif A. M. Almontashiri et al. PLoS One
- Profiling of Atherosclerotic Lesions by Gene and Tissue Microarrays Reveals PCSK6 as a Novel Protease in Unstable Carotid Atherosclerosis
- (2013) Ljubica Perisic et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis
- (2013) Hagai Tavori et al. CIRCULATION RESEARCH
- Short-Term Impact of Low-Dose Atorvastatin on Serum Proprotein Convertase Subtilisin/Kexin Type 9
- (2013) Yuan-Lin Guo et al. CLINICAL DRUG INVESTIGATION
- High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapy
- (2013) Wolfgang Koenig INTERNATIONAL JOURNAL OF CARDIOLOGY
- Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
- (2013) Kevin Fitzgerald et al. LANCET
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
- (2011) et al. EUROPEAN HEART JOURNAL
- Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study)
- (2010) K. A. A. Fox et al. EUROPEAN HEART JOURNAL
- Hepatocyte Nuclear Factor 1α Plays a Critical Role inPCSK9Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine
- (2009) Hai Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- HNF1α and SREBP2 are important regulators of NPC1L1 in human liver
- (2009) Camilla Pramfalk et al. JOURNAL OF LIPID RESEARCH
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
- (2009) J. C. Y. Chan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading Activity†
- (2008) Daping Fan et al. BIOCHEMISTRY
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
- (2008) Ahmed Zaid et al. HEPATOLOGY
- Lipid Levels After Acute Coronary Syndromes
- (2008) Bertram Pitt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
- (2008) GISSI-HF investigators LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started